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Introduction: Sleep-related hypoventilation should be considered in patients with chronic obstructive pulmonary
disease, because appropriate respiratory management during sleep is important for preventing elevation of PaCO2
levels. A nasal high-flow oxygen therapy system using a special nasal cannula can deliver suitably heated and
humidified oxygen at up to 60 L/min. Since the oxygen concentration remains a constant independent of minute
ventilation, this system is particularly useful in patients with chronic obstructive pulmonary disease who have
hypercapnia. This is the first report of sleep-related hypoventilation with chronic obstructive pulmonary
disease improving using a nasal high-flow oxygen therapy system.
Case presentation: We report the case of a 73-year-old Japanese female who started noninvasive positive-pressure
ventilation for acute exacerbation of chronic obstructive pulmonary disease and CO2 narcosis due to respiratory
infection. Since she became agitated as her level of consciousness improved, she was switched to a nasal high-flow
oxygen therapy system. When a repeat polysomnography was performed while using the nasal high-flow oxygen
therapy system, the Apnea Hypopnea Index was 3.7 times/h, her mean SpO2 had increased from 89 to 93%, percentage
time with SpO2 ≤ 90% had decreased dramatically from 30.8 to 2.5%, and sleep stage 4 was now detected for
38.5 minutes. As these findings indicated marked improvements in sleep-related hypoventilation, nasal high-flow
oxygen therapy was continued at home. She has since experienced no recurrences of CO2
narcosis and has been able to continue home treatment.
Conclusions: Use of a nasal high-flow oxygen therapy system proved effective in delivering a prescribed
concentration of oxygen from the time of acute exacerbation until returning home in a patient with chronic
obstructive pulmonary disease, dementia and sleep-related hypoventilation. The nasal high-flow oxygen therapy
system is currently used as a device to administer high concentrations of oxygen in many patients with type I
respiratory failure, but may also be useful instead of a Venturi mask in patients like ours with type II respiratory
failure, additionally providing some positive end-expiratory pressure.
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Table 1 Polysomnography data for before nasal high-
flow therapy system and nasal high-flow therapy system
Before NHFOTS NHFOTS
AHI (events/h) 12.1 3.7
AI (events/h) 0.26 0.0
HI (events/h) 11.9 3.7
Mean SpO2 (%) 89 93.0
Minimum SpO2 (%) 63 79
CT90 (%) 30.8 2.5
Sleep Stage 1 (min) 109.5 65.0
Sleep Stage 2 (min) 210.5 268.0
Sleep Stage 3 (min) 68.0 84.0
Sleep Stage 4 (min) 0.0 38.5
Sleep Stage REM (min) 72.0 85.5




SpO2: Oxygen Saturation of Arterial Blood Measured by Pulse Oximeter.
CT90: cumulative time percentage with SpO2 <90%.
REM: Rapid eye movement.
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Sleep-related hypoventilation (SRH) should be considered
in patients with chronic obstructive pulmonary disease
(COPD), because appropriate respiratory management
during sleep is important in preventing elevations in
PaCO2 levels. Variations in minute ventilation must be
considered in the respiratory management of COPD, and
the oxygen delivery system used should be capable of high
flow rates in which fractional inspired oxygen concentra-
tions (FiO2) do not vary with the patient’s breathing
pattern. We have previously reported that the average
volume-assured pressure support (AVAPS) ventilatory
mode was useful in achieving target minute ventilation in
a patient with acute exacerbation of COPD who had
sleep-disordered breathing.
We report herein the case of a patient in whom a nasal
high-flow oxygen therapy system (NHFOTS; Pacific-
Medico, Tokyo, Japan) and a biphasic positive airway
pressure (BiPAP) machine (Vivo 30; Breas Medical AB,
Mölnlycke, Sweden) were used for acute management of
COPD. The patient was able to be weaned from non-
invasive positive-pressure ventilation (NPPV), achieved
improvements in SRH, and was subsequently able to be
treated at home.
Case presentation
A 73-year-old Japanese female was being treated by a local
physician for hypertension, depression, dementia and in-
somnia. She developed flu-like symptoms in December
2013, and was diagnosed with influenza/cold by her phys-
ician. Clarithromycin (CAM) was prescribed. The next
day, her level of consciousness decreased, so she was trans-
ported to an urgent care facility. Marked hypoxemia and
hypercapnia were then identified, and she was transferred
to our hospital for further evaluation and treatment.
She had an axillary temperature of 37.2°C, a heart rate of
82 beats/min and regular, a respiratory rate of 14 breaths/
min (tachypneic), a blood pressure of 156/86mmHg, and
peripheral oxygen saturation (SpO2) of 79% (with nasal
oxygen at 2L/min). Her level of consciousness was
decreased (Glasgow Coma Scale: eye opening 4, verbal
response 3, motor response 5, total 12), but no pallor or
icterus was evident.
Her radiography revealed cardiomegaly and increased
transparency of the upper lung fields bilaterally, indicat-
ing emphysema. Her echocardiography revealed a mild
decrease in left ventricular ejection fraction (56%), right
atrial and ventricular enlargement, and an estimated pul-
monary systolic blood pressure of 57mmHg, indicating
moderate pulmonary hypertension.
Respiratory management for type II respiratory failure
was started with NPPV (ST mode; inspiratory positive
airway pressure 10cmH2O; expiratory positive airway
pressure 4cmH2O; ventilation rate 18 breaths/min; FiO230%). For right-sided heart failure with pulmonary hyper-
tension (clinical scenario, CS5), diuretics and a nitrite
were started. Hypercapnia gradually improved, but as her
level of consciousness improved, she became more agi-
tated and delirious due to dementia, and management by
mask became impossible. She was therefore switched to a
NHFOTS (oxygen, 5L/min; continuous positive airway
pressure (CPAP), 8cmH2O).
No recurrence of CO2 narcosis was seen subsequently,
and hypoxemia improved (SpO2, 94-96%). Using the
NHFOTS with a high flow rate, respiratory management
was able to be continued without any further agitation.
Her arterial blood gases (ABGs) were: pH 7.47, PaO2
57mmHg, PaCO2 62mmHg, and HCO3
− 41.5mmol/L.
Investigation of SRH by polysomnography (PSG) showed
an apnea-hypopnea index (AHI) of 12.1 events/h, and
SRH was therefore diagnosed. When a repeat PSG was
performed while using the NHFOTS, her AHI was 3.7
events/h, her mean SpO2 had increased from 89 to 93%,
the percentage time with SpO2 ≤90% had decreased dra-
matically from 30.8 to 2.5%, and sleep stage 4 (deep sleep),
which previously had not been observed, was now detected
for 38.5 minutes. These results indicated marked improve-
ments in SRH (Table 1).
Pulmonary function testing revealed severe obstructive
ventilatory impairment and decreased pulmonary diffu-
sion capacity. Based on the above test results, her classifi-
cation as grade 3 on the modified Medical Research
Council scale for exertional dyspnea, and her decreased
percentage-predicted forced expiratory volume in one
second, she was diagnosed with category D COPD, based
on the Global Initiative for Chronic Obstructive Lung
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discharged, and NHFOTS was started at home. As of the
time of writing, she is continuing treatment with the
NHFOTS at home, has shown no increases in PaCO2 (her
ABGs as of: pH 7.46, PaO2 85mmHg, PaCO2 41mmHg,
HCO3
− 29.2mmol/L), and is being followed up on.
Discussion
A wide range of evidence has shown that NPPV offers an
effective treatment for acute exacerbations of COPD
[1-3]. The GOLD guidelines also recommend NPPV,
since this method helps to avoid intubation, removes the
risk of nosocomial infections such as pneumonia during
intubated mechanical ventilation, and is effective in redu-
cing mortality rates [4]. In addition, we have previously
reported that the AVAPS mode was useful in achieving
target minute ventilation in a patient with acute exacer-
bation of COPD who had sleep-disordered breathing [5].
However, a key disadvantage of NPPV is that the method
is highly reliant on patient cooperation.
Our patient had dementia due to sequelae from a pre-
vious subarachnoid hemorrhage and stroke, as well as
agitation, depression and disturbance of sleep. She was
taking medications prescribed by her previous physician
including quetiapine, triazolam, flunitrazepam, etizolam,Nasal c
PM
Figure 1 Equipment used for the nasal high-flow oxygen therapy sys
and Vivo 30 ventilator, which uses a blower assembly to deliver high flowsulpiride and duloxetine. In such patients, continuous
NPPV can be difficult, and use of a NHFOTS with a nasal
cannula rather than a face mask can prove effective. We
therefore switched ventilatory support devices. The Ameri-
can Thoracic Society states that nasal high-flow oxygen
therapy using suitably warmed and humidified oxygen
represents a second-line option for oxygen delivery. The
NHFOTS uses a special nasal cannula and heated humidi-
fier and can deliver oxygen at maximum flow rates of 30 to
60L/min. Appropriate heating and humidification (37°C,
100% relative humidity) significantly enhances mucociliary
clearance without causing nasal discomfort [6].
In our patient, we used a PMH-2000 heated humidifier
(Pacific-Medico), a number 2 nasal cannula, and a Vivo
30 ventilator (Breas Medical AB), which uses a blower
assembly to deliver high flow rates (Figure 1). This sys-
tem enables nasal delivery of oxygen at high concentra-
tions and high flow rates. The advantages of a NHFOTS
are that patients can still eat and converse, oral care
is possible, there is less of an oppressive feeling com-
pared to wearing a mask, and patient quality of life is
improved [7]. In our patient with dementia and agitation
NHFOTS, unlike NPPV, was able to be continued. Nasal
high-flow oxygen therapy, mainly using a nasal high-
flow cannula (Optiflow™; Fisher & Paykel Healthcare,annula (No. 2)
ViVO 30
H200
tem. We used a PMH-2000 heated humidifier, number 2 nasal cannula
rates.
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quently been reported in the literature.
Parke et al. compared a NHFOTS and a face mask at an
oxygen flow rate of 35L/min in 15 patients after cardiac
surgery [8]. They reported that with the mouth closed,
mean airway pressure was higher with the NHFOTS
(2.7cmH2O) than with the face mask (0.2cmH2O) [8]. A
nasal high-flow cannula, compared to other oxygen deliv-
ery devices to date, can deliver nasal oxygen at very high
flow rates of up to 60L/min.
Figure 2 shows the relationship between different oxy-
gen flow rates and FiO2 with the NHFOTS we used. With
an oxygen flow rate of 30L/min, when oxygen is supplied
at 1L/min, the FiO2 is 24.4%. This is equivalent to using a
24% Venturi mask. Although greater leakage is seen with
this device, since a pressure of 8cmH2O is applied, some
PEEP (positive end-expiratory pressure) effect is also seen
in comparison to a Venturi mask. When 2.5L/min of oxy-
gen is supplied, the FiO2 is 28.5%, similar to that with a
28% Venturi mask. In England, the guidelines for oxygen
therapy in acute COPD patients recommend using a
Venturi mask, in which by setting the maximum inspira-
tory flow above the tidal volume of the patient, an accur-
ate oxygen concentration can be delivered independent
of the patient’s minute ventilation [9].
With Venturi masks, many types of devices are
needed, depending on the oxygen concentration deliv-
ered and due to the need for high flow rates. As a re-
sult, use of these masks is associated with several
disadvantages, including high noise levels, facial andFigure 2 Relationship between FiO2 and oxygen flow. CPAP, continuoueye irritation, impaired ability to speak and inconvenience
for patients when eating. A NHFOTS, by compensating
for these disadvantages and using a high-flow oxygen
blender, can deliver oxygen at high flow rates up to
60L/min. With nasal high-flow oxygen therapy using a
Vivo ventilator, by supplying oxygen at a maximum flow
of 15L/min, a 70% oxygen concentration can be achieved,
even higher than with a conventional Venturi mask
(Figure 2). By increasing CPAP to 8, 13 or 20cmH2O,
oxygen flow rates can be increased to 30, 40 and 50L/
min, respectively. Therefore, unlike a Venturi mask, a
NHFOTS can even be used in patients with high minute
volumes, such as those who have interstitial lung dis-
ease. It is important to understand that by increasing
CPAP, the oxygen concentration is decreased even at
the same oxygen flow rate (Figure 2). Specifically, for
every 1-L/min increase in oxygen, oxygen concentration
increases by 3.36% (30L/min), 2.56% (40L/min) and
2.03% (50L/min).
The results from the PSG in our patient confirmed the
presence of sleep apnea syndrome (SAS) with an AHI of
12.1 events/h. This type of SRH can be dramatically im-
proved using a NHFOTS during sleep (Table 1), because
although the oxygen concentration is low with oxygen
supplied at 1.5L/min, the high flow system has a supply
flow rate ≥30L/min that, by exerting positive pressure,
improves sleep-disordered breathing.
Many factors are involved in the mechanisms of sleep-
related alveolar hypoventilation in COPD [10]. Since
breathing in COPD patients is highly dependent ons positive airway pressure.
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decreased muscle tone during rapid eye movement
(REM) sleep increases alveolar hypoventilation. In
addition, factors such as decreased functional reserve
capacity, increased upper airway resistance and worsening
ventilation-perfusion mismatch result in marked hypox-
emia, particularly during REM sleep. This sleep hypoxemia
increases pulmonary artery pressure, worsening right-sided
heart failure [11]. Furthermore, arrhythmias and polycy-
themia may develop, increasing the mortality rate [12].
Home NPPV is indicated in patients like ours with a
PaCO2 ≥55mmHg, persistent nocturnal hypoventilation
and cor pulmonale. However, if sleep hypoxemia is
present, injudicious oxygen administration without taking
SRH into consideration can lead to marked hypercap-
nia. COPD patients, especially those with pulmonary
hypertension, should therefore undergo measurement
of nighttime oxygen saturation. If oxygen saturation is
decreased, PSG should be performed and an appropriate
level of oxygen should be prescribed. Regarding acute
exacerbations, Austin et al. conducted a cluster random-
ized parallel-group trial in 405 patients with presumed
acute exacerbation of COPD during ambulance transport,
to compare high-flow oxygen therapy with titrated oxygen
therapy [12]. The mortality rate was significantly decreased
in the titrated oxygen group (4 versus 9%), and patients in
this group with confirmed COPD showed significantly less
respiratory acidosis and hypercarbia [12]. With injudicious
oxygen administration during sleep, this type of event is
likely to recur at night.
Nasal high-flow oxygen therapy essentially requires an
oxygen blender. In some settings, such as hospital wards or
homes without air supply pipes, an oxygen blender using a
Venturi method that can be used with oxygen tubing alone
is necessary. This type of set up and oxygen supply is com-
plex. For our patient, we used a modified nasal cannula
and PMH-2000 heated humidifier (Pacifico-Medico) and a
Vivo 30 ventilator (Breas Medical AB), without using the
Venturi method. This system is quiet and convenient
for home use. Continued use at home is possible even in
patients with dementia, such as our patient, allowing
improvements in PaCO2.
The disadvantage of a NHFOTS is that ventilatory sup-
port is not as effective as NPPV. Reports to date have
therefore recommended consideration of NPPV or intu-
bated mechanical ventilation if the respiratory rate and
oxygenation have not improved within 4 to 6 hours. Fur-
ther studies evaluating the use of NPPV for respiratory
failure in COPD patients involving a larger number of
patients are needed [13,14].
Conclusion
The use of a NHFOTS was effective for delivering a
prescribed concentration of oxygen from the time ofacute exacerbation until discharge to home in our patient
with COPD who also had dementia and SRH. This safe
oxygen therapy enabled improvements in sleep-related
alveolar hypoventilation. The NHFOTS is currently used
as a device to administer high concentrations of oxygen in
many patients with type I respiratory failure, but may also
be useful instead of a Venturi mask in patients like ours
with type II respiratory failure, in addition to providing
some PEEP effect.
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